IP Library Granted Patent US 11,363,951
Granted Patent B2
US 11,363,951 · App. 13/612,545 · Granted Jun 21, 2022

Intraocular physiological sensor

Inventors: Thomas W. Burns (Dana Point, CA); Harold A. Heitzmann (Irvine, CA); Kenneth Martin Curry (Oceanside, CA); David S. Haffner (Mission Viejo, CA); David Applegate (Palm Springs, CA); Bruce Nogales (Raleigh, NC)
Assignee: GLAUKOS CORPORATION
A61B3/16A61B5/0031A61B5/076A61B5/1112A61B5/1473A61B5/14503A61B5/14507A61B5/14532A61B5/4836A61B5/4839A61B5/6821A61B5/6867A61B5/6882A61B5/7246G16H10/60G16H20/10G16H50/30H01M8/16A61B2562/0247
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,363,951
App. No.
13/612,545
Granted
Jun 21, 2022
Kind
B2
Abstract

An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.

Claims (22)

1. An implantable physiological measurement device comprising:

a sensing module configured to output a signal representative of intraocular pressure in the anterior chamber of a patient's eye;

an antenna configured to wirelessly communicate intraocular pressure measurements to an external device;

a battery configured to supply operating power to the device; and

an elongate housing configured to house the sensing module, the antenna, and the battery, such that the sensing module, the antenna, and the battery are disposed inside the elongate housing, the elongate housing being sized and shaped to be at least partially implanted in the supraciliary/suprachoroidal space of the patient's eye,

wherein the sensing module is disposed within the elongate housing at a first end of the elongate housing, such that the sensing module resides in the anterior chamber of the patient's eye when an opposite second end of the elongate housing, along with at least a portion of the antenna or battery, resides in the supraciliary/suprachoroidal space, and

wherein the implantable physiological measurement device is configured to be delivered to the supraciliary/suprachoroidal space via a self-trephinating wire extending beyond the second end of the elongate housing, wherein the implantable physiological measurement device comprises a passage through which the self-trephinating wire could be threaded, wherein a pusher is configured to contact the implantable physiological measurement device at the first end of the elongate housing, and wherein each of the pusher, the self-trephinating wire, and the implantable physiological measurement device are configured to translate within a sheath.

2. The device of claim 1 , wherein the sensing module is further configured to output a signal representative of glucose concentration in the aqueous humor of the eye.

3. The device of claim 1 , further comprising a measurement storage device that is configured to store measurements of the intraocular pressure.

4. The device of claim 1 , wherein the device is configured to automatically measure intraocular pressure at least every hour.

5. The device of claim 1 , wherein the device is configured to automatically measure intraocular pressure at least every 15 minutes.

6. The device of claim 1 , wherein the device is configured to automatically measure intraocular pressure at least every minute.

7. The device of claim 1 , wherein the elongate housing is biocompatible.

8. The device of claim 1 , wherein the battery has a power output of at least about 10 μW.

9. The device of claim 1 , wherein one or more components of the device are provided on a carrier member located within the elongate housing.

10. The device of claim 9 , wherein the carrier member is flexible.

11. The device of claim 10 , wherein the carrier member comprises a circuit board.

12. The device of claim 1 , further comprising a drug repository.

13. The device of claim 1 , wherein the second end of the elongate housing includes a barbed retention feature to maintain the position of the device within the supraciliary/suprachoroidal space of the eye.

14. The device of claim 1 , wherein the elongate housing has a width of 0.6 mm or less.

15. The device of claim 1 , wherein the elongate housing has a length of 22 mm or less.

16. A method of using the device of claim 1 , the method comprising inserting the device into a human eye such that the sensing module resides in the anterior chamber of the eye and such that the elongate housing is at least partially provided in the supraciliary/suprachoroidal space of the eye.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2017
From: DOSE MEDICAL CORPORATION
To: GLAUKOS CORPORATION
Reel/Frame 042251/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2014
From: BURNS, THOMAS W; HEITZMANN, HAROLD A; CURRY, KENNETH MARTIN; HAFFNER, DAVID S; APPLEGATE, DAVID; NOGALES, BRUCE
To: DOSE MEDICAL CORPORATION
Reel/Frame 032963/0609 →
Continuity (4)
Provisional Application 61534324 · Sep 13, 2011
Provisional Application 61542097 · Sep 30, 2011
Provisional Application 61561230 · Nov 17, 2011
Related Publication 20130090534A1 · Apr 11, 2013
Cited By (3)
US 12,274,640 US 12,458,535 US 12,514,750